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Abstract Cardiac sodium channel are protein complexes
that are expressed in the sarcolemma of cardiomyocytes to
carry a large inward depolarizing current (INa) during phase
0 of the cardiac action potential. The importance of INa for
normal cardiac electrical activity is reflected by the high
incidence of arrhythmias in cardiac sodium channelopathies,
i.e., arrhythmogenic diseases in patients with mutations in
SCN5A, the gene responsible for the pore-forming ion-
conducting α-subunit, or in genes that encode the ancillary
β-subunits or regulatory proteins of the cardiac sodium
channel. While clinical and genetic studies have laid the
foundation for our understanding of cardiac sodium channe-
lopathies by establishing links between arrhythmogenic
diseases and mutations in genes that encode various subunits
ofthecardiacsodiumchannel,biophysicalstudies(particularly
in heterologous expression systems and transgenic mouse
models) have provided insights into the mechanisms by which
INa dysfunction causes disease in such channelopathies. It is
now recognized that mutations that increase INa delay cardiac
repolarization, prolong action potential duration, and cause
long QT syndrome, while mutations that reduce INa decrease
cardiac excitability, reduce electrical conduction velocity, and
induce Brugada syndrome, progressive cardiac conduction
disease, sick sinus syndrome, or combinations thereof.
Recently, mutation-induced INa dysfunction was also linked
to dilated cardiomyopathy, atrial fibrillation, and sudden
infant death syndrome. This review describes the structure
and function of the cardiac sodium channel and its various
subunits, summarizes major cardiac sodium channelopathies
and the current knowledge concerning their genetic back-
ground and underlying molecular mechanisms, and discusses
recent advances in the discovery of mutation-specific
therapies in the management of these channelopathies.
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Introduction
Cardiac sodium channels are transmembrane proteins that
are located in the sarcolemma of atrial and ventricular
myocytes and the Purkinje fibers. They enable a large and
rapid influx of sodium ions (sodium current; INa) during the
rapid upstroke (phase 0) of the cardiac action potential. INa
underlies the initiation and propagation of action potentials,
and, by doing so, it determines cardiac excitability and
conduction velocity of electrical stimuli through the heart
(Fig. 1a, b)[ 9]. To a lesser extent, cardiac sodium channels
are also present in the sinoatrial node and the atrioventric-
ular node, where they contribute to pacemaker activity [45].
The importance of sodium channels for normal electrical
activity of the heart is emphasized in arrhythmogenic
diseases caused by inherited or de novo (mostly heterozy-
gous) mutations in SCN5A, the gene that encodes the cardiac
sodium channel (“cardiac sodium channelopathies”). These
diseases include long QTsyndrome type 3 (LQT-3), Brugada
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(PCCD), dilated cardiomyopathy (DCM), sick sinus syn-
drome (SSS), atrial fibrillation (AFib), sudden infant death
syndrome (SIDS), and overlap syndromes [5]. In overlap
syndromes, patients display overlapping clinical symptoms
or arrhythmia forms of more than one disease [42]. Although
less prevalent, mutations in genes encoding proteins that
regulate the expression or function of the sodium channel
may also cause these diseases [5].
The effects of SCN5A mutations on the normal structure,
expression, and function of cardiac sodium channels are
routinely investigated by cloning and expression of channel
proteins in heterologous systems (e.g., human embryonic
kidney cells, Chinese hamster ovary cells, Xenopus
oocytes). The effects of mutations in genes encoding the
regulatory proteins are studied by co-expression of the
mutant protein with the normal sodium channel protein.
Additionally, genetically engineered mice carrying mutations
in a specific gene of interest are increasingly used to study the
effect of mutations in the native environment of the myocyte
[17]. These expression models, in conjunction with various
experimental techniques (e.g., electron crystallography to
study channel structure, polymerase chain reaction to study
mRNA expression, Western blot and immunohistochemistry
to study protein expression, co-immunoprecipitation to study
protein–protein associations, and patch-clamp technique to
measure currents) have greatly enhanced our understanding
of the role of sodium channel dysfunction in the pathophys-
iology of cardiac sodium channelopathies. Furthermore, they
have provided basic rationale for gene-specific and even
mutation-specific approaches in the clinical management of
subject with such channelopathies. This review briefly
describes the structure and function of the cardiac sodium
channel and its modulation by regulatory proteins. Moreover,
it discusses the well-recognized cardiac sodium channelopa-
thies and the nature and role of sodium channel dysfunction
in the underlying mechanisms of these diseases.
The cardiac sodium channel
Voltage-gated sodium channels are dynamic transmembrane
proteins in excitable cells (e.g., cardiomyocytes, skeletal
muscle cells, neurons) that open and close to conduct ions.
They are large molecular complexes containing a pore-
forming ion-conducting α-subunit and ancillary β-subunits,
and several regulatory proteins [1, 9, 29, 33, 39, 48, 77, 89].
The α-subunit is called Nav1.5, and is encoded by SCN5A.I t
is organized into a cytoplasmic N terminus, four homologous
domains (DI–DIV) that are connected to each other by
Fig. 1 The cardiac electrical activity and cardiac ion currents. a The
electrical activity of the heart is represented on the surface
electrocardiogram (ECG), and results from coordinated action poten-
tial generation in individual cardiomyocytes. The electrical activity
starts by the spontaneous generation of action potentials in pacemaker
cells in the sinoatrial node. Propagation of these action potentials
creates an excitation wave through the atria, leading to atrial
depolarization. After traveling through the atrioventricular node, the
excitation wave reaches the ventricles, and leads to ventricular
depolarization. b The cardiac action potential is generated by
transmembrane inwardly and outwardly directed ion currents. The
inward (depolarizing) sodium and calcium currents are pointed
downwards and colored blue. The outward (repolarizing) potassium
currents are pointed upwards and colored green
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domain consists of six transmembrane α-helical segments
(S1–S6), connected to each other by alternating extracellular
and cytoplasmic loops. The four domains fold around an ion-
conducting pore, which is lined by the extracellular loops
(P-loops) between S5 and S6 segments (Fig. 2a, b). Some
amino acids in the P-loops confer the selectivity for sodium
ions. Gating represents time-dependent transitions between
distinct conformational states of the channel protein due to
molecular movements in response to membrane potential
changes (“voltage-dependent gating”)[ 9]. When cardiomyo-
cytes are excited by electrical stimuli from adjacent cells or
by artificially applied stimuli during patch-clamp experiments,
their resting membrane potential (approximately −85 mV)
depolarizes. This triggers an outward movement of the
positively charged S4 segments (voltage sensors), which leads
to channel activation (i.e., opening of the pore). Inactivation
(closing of the pore) starts simultaneously with activation, but
since inactivation is slower than activation, channels remain
transiently open to conduct INa during phase 0 of the action
potential (Fig. 3a, b). Inactivation comprises different
conformational states, including fast, intermediate, and slow
inactivation. Fast inactivation is coupled to activation and
initiated by the outward movement of the S4 segment of DIV.
This triggers the amino acids isoleucine, phenylalanine, and
methionine (IFM motif; “the lid”) and the neighboring
glycine and proline (“the hinges”) in the DIII–DIV linker to
occlude the pore by binding to multiple amino acids in the
cytoplasmic loops between the S4 and S5 segments of DIII
and DIV (“the dock”)[ 9]. The molecular movements leading
to slow inactivation are less well understood. However,
mutations in the P-loops, the S6 segments and the C terminus
have been reported to affect this state. In any case, more than
99% of sodium channels are inactivated at the end of action
potential phase 1, and can be reactivated only after recovery
from inactivation during action potential phase 4. Slow
inactivation requires much longer recovery times than fast
inactivation. Finally, a very small fraction of sodium channels
may reactivate during action potential phase 3. The current
through these channels (<1% of the peak INa) is called the
window current, since it arises when the sarcolemma reaches
a potential that is depolarized sufficiently to reactivate some
channels, but not enough to cause complete inactivation
(Fig. 3c, d). The voltage range for the window current is very
restricted and narrow in healthy hearts, granting it a small role
during the cardiac action potential [41].
Although Nav1.5 is sufficient to generate sodium current
in heterologous expression systems, the obtained current is
quite different from INa present in isolated cardiomyocytes.
This may be due to the absence of ancillary β-subunits and
regulatory proteins in heterologous systems (Fig. 2b). So
far, four β-subunits are known in the heart (β1t oβ4),
which are encoded by four genes (SCN1B to SCN4B)
[1, 29, 33, 48, 89]. The β-subunits are proteins with an
extracellular N terminus, one transmembrane segment, and
a cytoplasmic C terminus. They increase the expression of
Fig. 2 Molecular structure of
the cardiac sodium channel.
a Cartoon of the α-subunit
(Nav1.5) and the β-subunit of
the cardiac sodium channel.
Nav1.5 consists of four domains
(DI–DIV), each containing six
transmembrane segments
(S1–S6); S4 segments are
positively charged and act as
voltage sensors. The β-subunit
consists of one single
transmembrane segment. b The
four domains of Nav1.5 fold
around an ion-conducting pore,
which is lined by the loops
between the S5 and S6
segments. The expression and
function of Nav1.5 is regulated
by β-subunits and several
directly or indirectly
interacting regulatory proteins
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modulate its gating properties, and play crucial roles in
the interaction of Nav1.5 proteins to extracellular matrix
molecules, cytoplasmic cytoskeleton apparatus, and com-
ponents of cardiac intercellular junctions (e.g., cadherins,
connexins). The β-subunits may also contribute to the
preferential localization of Nav1 . 5p r o t e i n si nt h ei n t e r c a l a t e d
disks. Nav1.5 proteins may also directly interact with several
regulatory proteins, including enzymes involved in their
glycosylation and phosphorylation (e.g., Ca
2+/calmodulin-
dependent protein kinase II) [1, 77], adaptor proteins that
connect them to the cytoskeleton (e.g., ankyrins) [77], and
proteins that mediate their trafficking from the endoplasmic
reticulum (ER) to the sarcolemma (e.g., glycerol-3-
phosphate dehydrogenase 1-like protein) [39]. Of note,
mutations in genes encoding β-subunits and regulatory
proteins are occasionally found in patients with clinical
phenotypes similar to arrhythmogenic diseases caused by
SCN5A mutations. This reflects the importance of these
proteins for the normal functioning of the cardiac sodium
channel [5].
Long QT syndrome type 3
Long QT syndrome (LQTS) is a disease characterized by
prolonged QT intervals on the surface electrocardiogram
(ECG), and increased risk for sudden death due to
ventricular tachyarrhythmias, in particular torsades de
pointes. Prolonged QT intervals reflect increased action
potential durations in ventricular myocytes, and correspond
with delayed ventricular repolarization (Fig. 4a, b). Heritable
LQTS is classified into different types, and each type is
linked to mutations in a gene encoding a protein that is
directly (ion channel) or indirectly (β-subunit or regulatory
protein) involved in repolarization [50]. LQT-3 is linked to
mutations in SCN5A, and covers approximately 13% of all
genotyped individuals with LQTS [31, 87]. So far, more than
Fig. 3 Voltage-dependent activation and inactivation of the cardiac
sodium channel. a Using the patch-clamp technique, the membrane
potential dependence of activation is studied by applying 50 ms
depolarizing voltage steps from a holding potential of −120 mV
(inset). The activation curve is obtained by dividing the amplitude of
the resulting sodium current at each voltage step by the maximum
peak sodium current amplitude, and plotting versus the corresponding
voltage. b The membrane potential dependence of inactivation is
studied by applying 500 ms depolarizing voltage steps from a holding
potential of −120 mV to inactivate the channels (prepulse). Next, the
fraction of channels that is not inactivated by the prepulse is measured
by applying a voltage step to 20 mV (test pulse). The inactivation
curve is obtained by dividing the amplitude of sodium current at each
test pulse by the maximum peak sodium current amplitude, and
plotting versus the corresponding prepulse voltage. c The window
current (gray area) arises when the sarcolemma reaches a potential
that is depolarized sufficiently to reactivate some channels, but not
enough to cause complete inactivation. d The voltage range for the
window current is normally narrow and achieved during phase 3 of
the ventricular action potential
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LQT-3, and nearly 50% of them have been studied
heterologously [93]. Most of these mutations are missense
mutations, and are found to cause sodium channel gain-of-
function, by disrupting fast inactivation and thereby causing
an abnormal sustained (or persistent) non-inactivating sodium
current(Isus or Ipst;F i g .4c, d)[ 13]. Mutations causing Isus are
mainly clustered in Nav1.5 regions that are involved in fast
inactivation (i.e., S4 segment of DIV, the DIII–DIV linker,
and the cytoplasmic loops between the S4 and S5 segments
of DIII and DIV), or in regions that stabilize fast inactivation
(e.g., the C terminus) [31, 52, 76, 93]. The C terminus
probably interacts with the DIII–DIV linker to stabilize the
occlusion of the pore during inactivation [60].
Other less common mechanisms of SCN5A mutations to
cause LQT-3 include increased window current [86, 90],
slowerinactivation[66, 90], faster recovery from inactivation
[2, 19], and larger peak INa density [64]. The window current
increases when inactivation of mutant sodium channels
occurs at more positive (depolarized) potentials (i.e., delayed
inactivation), while activation is not changed. This widens
the voltage range during which the sodium channel may
reactivate without inactivation (Fig. 5a)[ 86, 90]. Slower
inactivation allows longer channel openings, and causes a
slowly inactivating sodium current (Fig. 5b)[ 66, 90]. To
distinguish it from Isus (which does not inactivate), this
current is called the late sodium current (INaL)i nt h i sr e v i e w .
However, in the literature, the terms Isus,I pst,a n dI NaL are
often used interchangeably. Comparable to Isus,b o t ht h e
window current and INaL exert their effects during phases 2
and 3 of the action potential, where normally no or very
small sodium current is present. However, the other two
mechanisms (i.e., faster recovery from inactivation and larger
peak INa density) involve increased influx of sodium ions
during phase 0 of the action potential (Fig. 5c). Faster
recovery from inactivation leads to larger peak INa by
increasing the fraction of channels available for activation
during subsequent depolarizations. Finally, larger INa density
may result from increased expression of mutant Nav1.5
through enhanced mRNA translation or protein trafficking to
the sarcolemma, decreased protein degradation, or altered
modulation by β-subunits and regulatory proteins. Impor-
tantly, one single SCN5A mutation may cause several
changes in the expression and/or gating properties of the
resulting sodium channels. Regardless of the mechanism,
increased sodium current (Isus, window current, INaL,o rp e a k
INa) upsets the balance between depolarizing and repolarizing
currents in favor of depolarization. The resulting delay in the
repolarization process triggers early afterdepolarizations (i.e.,
re-activation of L-type calcium channel during phases 2 or 3
of the action potential), especially in Purkinje fiber myocytes
where action potential durations are intrinsically longer
[22, 27]. Early afterdepolarizations are believed to induce
torsades de pointes [92].
Arrhythmic events in LQT-3 usually occur at rest or
during sleep when the heart rate is slow. Accordingly, Isus is
larger at slower stimulus frequencies, suggesting that the
degree of Isus may be a strong determinant for arrhythmias
to occur [70]. This is confirmed by a report of homozygous
carriers of an SCN5A mutation who displayed longer QT
intervals and more frequent arrhythmias than heterozygous
carriers of the same mutation. Consistently, homozygous
expression of the mutation in heterologous system caused
larger Isus densities than heterozygous expression of the
mutation [40]. The definite role of Isus in LQT-3 is further
reflected by the effectiveness of drugs that inhibit Isus in the
treatment of patients with LQT-3. Such drugs (e.g., ranola-
Fig. 4 Long QT syndrome type 3. a Prolonged QT intervals on the
surface ECG of an individual with LQT-3. b QT interval prolongation
results from delayed repolarization of ventricular action potentials. c
Delayed repolarization in LQT-3 is often due to the presence of
abnormal sustained non-inactivating sodium current (green area). d
Sustained current results from incomplete inactivation of the sodium
channels (green circles)
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with LQT-3 by preferentially blocking Isus over peak INa
[11, 51, 69]. However, this effect may be mutation specific.
Mexiletine has been shown to be especially effective in
patients with SCN5A mutations that shift inactivation toward
more negative potentials (i.e., earlier inactivation) [66].
Moreover, in high concentrations these drugs may also block
peak INa, and exert pro-arrhythmic effects by decreasing
cardiacexcitabilityandslowingelectricalconductionvelocity.
Finally, beta-blockers (the cornerstone therapy in most long
QT syndrome patients, particularly those with LQTS type 1
and, somewhat less so, in LQTS type 2) seem to be less
effective in LQT-3 [70]. This may be due to their pro-
arrhythmic effect by slowing the heart rate and consequently
increasing Isus, which opposes their anti-arrhythmic effect
(i.e., preferential block of Isus by direct binding to Nav1.5).
The anti-arrhythmic effect of beta-blockers in LQT-3 may
also be mutation-specific (e.g., when inactivation occurs at
more negative potentials), and limited to some agents
(propranolol, carvedilol, but not metoprolol) [10].
LQTS and mutations in sodium channel regulatory proteins
Three less common types of LQTS are caused by mutations
in genes encoding proteins that regulate the expression or
function of Nav1.5 proteins. A mutation in SCN4B,
encoding the β4-subunit, has been linked to LQTS type
10. When co-expressed heterologously with SCN5A, the
mutation shifted the inactivation toward more positive
potentials, but did not change the activation. This resulted
in increased window currents at membrane potentials
corresponding to the phase 3 of the action potential [48].
Mutations in CAV3, encoding caveolin-3, are linked to
LQTS type 9 (LQT-9). Caveolin-3 co-localizes and interacts
with Nav1.5 proteins at the sarcolemma of cardiomyocytes
(Fig. 2b). When co-expressed with SCN5A, the mutant
caveolin-3 proteins induce Isus through a yet unknown
mechanism [81]. Finally, a mutation in SNTA1 has been
linked to LQTS type 12. SNTA1 encodes α1-syntrophin, a
cytoplasmic adaptor protein that enables the interaction
between Nav1.5, nitric oxide synthase (NOS), and sarcolem-
mal calcium ATPase (PMCA). PMCA inhibits nitric oxide
synthesis by NOS. By inducing nitrosylation of Nav1.5
proteins, nitric oxide decreases channel inactivation and
increases Isus densities. The mutation in SNTA1 disrupted
the interaction between Nav1.5 and PMCA, and conse-
quently caused increased Nav1.5 nitrosylation and Isus
densities [77].
Brugada syndrome
BrS is diagnosed in subject with high risk for sudden death
due to ventricular tachyarrhythmias (polymorphic ventricular
tachycardia and ventricular fibrillation), accompanied by
typical coved-type ST segment elevation in the right-
precordial ECG leads V1 to V3 [16]. The ECG changes are
often concealed, but can be unmasked by a drug challenge
test using Class 1A or 1C anti-arrhythmic drugs (e.g.,
ajmaline, flecainide, pilsicainide), which block the cardiac
sodium channel (Fig. 6a)[ 91]. This indicates the crucial role
of INa inhibition in the pathophysiology of BrS. Accordingly,
10–30% of subject with BrS carry a mutation in SCN5A,
including missense mutations, nonsense mutations, and
nucleotide deletions or insertions [91, 93]. The latter may
alter mRNA splicing or create a premature stop codon by
shifting the open reading frame, and result in truncated
Nav1.5 proteins. More than 100 SCN5A mutations are linked
Fig. 5 Alternative mechanisms
of sodium channel gain-of-
function in long QT syndrome
type 3. a Increased window
current due to delayed
inactivation of cardiac sodium
channels (green circles).
Increased windows current is
carried at potentials
corresponding to phases 2
and 3 of the ventricular action
potential (green area), remote
from the peak sodium current
during phase 0 (blue area).
b Slower inactivation creates a
late sodium current (green area).
c Increased peak sodium current
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expressed (<50%) lead to sodium channel loss-of-function
(i.e., reduced peak INa; Fig. 6b). The underlying mechanisms
include decreased expression of Nav1.5 proteins [78],
expression of non-functional channels [35], and altered
gating properties [6, 15, 21, 73]. Decreased sarcolemmal
expression of Nav1.5 proteins results from premature
degradation of the mutant proteins by the quality control
system in the ER (Fig. 7a)[ 78]. Expression may also be
decreased because mutant Nav1.5 proteins fail to interact
with β-subunits or regulatory proteins, which mediate their
normal localization on the sarcolemma. Some mutant Nav1.5
proteins pass the ER quality control system and traffic
normally to the sarcolemma, but form channels that conduct
no or very small INa (non-functional) [35]. The third
mechanism (altered gating properties) comprises delayed
activation (i.e., activation at more positive potentials) [73],
earlier inactivation (i.e., inactivation at more negative
potentials) [15], faster inactivation [21], and enhanced slow
inactivation [6]. Delayed activation, earlier inactivation, and
faster inactivation reduce INa by decreasing the probability of
the channels to reside in the activated state (Fig. 7b, c).
Enhanced slow inactivation means that mutant channels
preferentially enter into the slow inactivation state. As
mentioned earlier, the slow inactivation state requires
relatively long recovery times during the action potential
phase 4. At fast heart rates, phase 4 becomes too short for
such channels to recover completely from slow inactivation.
This leads to an accumulation of the channels in the slow
inactivation state, and INa reduction. Although BrS-linked
SCN5A mutations are in general randomly located in various
regions of Nav1.5, mutations that cause enhanced slow
inactivation are mainly located in the P-loops, the S6
segments, and the C terminus [93].
INa reduction decreases the upstroke velocity of action
potential phase 0, and, as a result, slows atrial and
ventricular electrical conduction (Fig. 6c). This is often
reflected by prolonged atrioventricular and ventricular
conduction intervals (PR and QRS intervals, respectively)
on the ECGs of BrS patients with an SCN5A mutation
(Fig. 6a)[ 91]. During electrophysiological studies in such
patients, electrical conduction is particularly delayed between
the His bundle and the ventricles (HV interval prolongation),
indicating the importance of INa for the initiation and
propagation of action potentials in Purkinje fiber myocytes
and the ventricular conduction system [72]. The right-
precordial ST segment elevation is less well understood,
and explained by two hypotheses. The first hypothesis
focuses on the presence of transmural voltage gradients due
to heterogeneity in action potential duration between the
right ventricular epicardium and endocardium. Indeed, action
potential durations are shorter in the epicardium, where the
repolarizing transient outward potassium current (Ito)i sm o r e
prominently expressed. INa reduction would further shorten
epicardial action potential durations, and facilitate reentrant
excitation waves between depolarized endocardium and
prematurely repolarized epicardium [7]. The second hypoth-
esis involves preferential conduction slowing in the right
ventricular outflow tract. Regional differences in conduction
velocity in the right ventricular epicardium would be
aggravated by INa reduction, and trigger the occurrence of
epicardial reentrant excitation waves [49]. This hypothesis is
supported by the increased prevalence of mild (subclinical)
structural abnormalities in the right ventricles of BrS patients
Fig. 6 Brugada syndrome.
a Coved-type ST segment
elevation in the right-precordial
ECG leads V1 and V2 after
intravenous (i.v.) administration
of sodium channel blocking
drug ajmaline in an individual
with BrS. b BrS-linked SCN5A
mutations often lead to peak
sodium current reduction.
c Reduced peak sodium current
decreases the upstroke velocity
of action potential phase 0,
which slows cardiac electrical
conduction
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[24]. Regardless of the mechanism, since ST segment
elevation is equally seen in SCN5A mutation carriers and
non-carriers, other genetic variants (e.g., in genes encoding
ion channels or regulatory proteins) and exogenous factors
(e.g., electrolyte imbalances, hormones, body temperature)
may contribute to the pathophysiology of BrS [4, 30, 46, 74].
Arrhythmic events in BrS occur more frequently in men,
and at rest or during sleep. Experimental studies suggest
that the effects of gender on the BrS phenotype may be due
to intrinsic differences in ion channel expression between
men and women (e.g., higher Ito densities in men) or due to
differences in hormone levels (e.g., higher testosterone
levels in men) [7, 74]. The latter is confirmed by the
disappearance of typical BrS ECG changes after castration
[46]. The occurrence of arrhythmias during sleep may be
due to an increased vagal activity and/or decreased
sympathetic activity. This is confirmed in BrS patients by
right-precordialSTsegmentelevationfollowingintracoronary
injection of acetylcholine, and decreased levels of norepi-
nephrine inthe synapticcleft onpositron emissiontomography
[32, 54]. Moreover, the typical ECG changes and arrhythmias
in BrS may also be triggered by fever [4]. Although the
mechanism is not fully understood, some SCN5A mutations
have been shown to alter the gating properties of cardiac
sodium channels in a temperature-dependent manner, e.g.,
more slow inactivation at higher temperatures [6, 21]. Finally,
the BrS ECG changes are reported to worsen during exercise.
This may be partially attributed to an enhanced slow
inactivation in mutant channels, leading to an accumulation
of the mutant channels in the slow inactivation state at fast
heart rates. However, other factors (e.g., autonomic nervous
system, ion current imbalances) may also play a role [3].
So far, no mutation-specific therapy is available for BrS.
Decreased sarcolemmal expression of mutant Nav1.5
proteins can be restored with cardiac sodium channel
blocking drugs (e.g., mexiletine). Such drugs bind to
mutant proteins, and act as molecular chaperones to rescue
their trafficking from the ER to the sarcolemma [78].
However, it is questionable whether these drugs can be used
as therapy, because (once expressed on the sarcolemma) the
mutant proteins display arrhythmia-causing gating defects
(e.g., Isus)[ 58]. Moreover, since sodium channel blocking
drugs reduce INa, they may aggravate ECG changes or
trigger arrhythmias in BrS, and should therefore be avoided
[30, 59]. An implantable cardioverter defibrillator and
adequate treatment of fever are currently the only effective
therapies to prevent sudden death in BrS.
BrS and mutations in sodium channel regulatory proteins
INa reduction in BrS may also be due to mutations in genes
encoding β-subunits or regulatory proteins of the cardiac
sodium channel. A mutation in SCN1B was found in one
Fig. 7 Mechanisms of sodium
channel loss-of-function in
Brugada syndrome, progressive
cardiac conduction disease,
and sick sinus syndrome.
a Decreased sarcolemmal
expression of Nav1.5 due to
premature degradation of
mutant channel proteins by the
quality control system in the
endoplasmic reticulum.
b Delayed activation of cardiac
sodium channels (red circles).
c Earlier inactivation of cardiac
sodium channels (red circles)
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mutation resulted in formation of truncated β1-subunits,
which failed to interact with Nav1.5 proteins and to increase
INa densities as normal β1-subunits did [89]. A missense
mutation in SCN3B was found in one subject with BrS. The
mutation reduced INa by disrupting the trafficking of Nav1.5
proteins from the ER to the sarcolemma, and by altering the
gating properties (e.g., earlier and faster inactivation) [29].
Finally, a mutation in GPD1-L, encoding glycerol-3-
phosphate dehydrogenase 1-like protein (GPD1-L), was
found in a family with BrS [39]. Recently, GPD1-L was
shown to inhibit the phosphorylation of Nav1.5 proteins at
residues where phosphorylation would lead to INa reduction
(probably by decreasing the sarcolemmal expression of
Nav1.5 proteins). The mutant GPD1-L failed to inhibit the
phosphorylation of Nav1.5 proteins, and resulted in reduced
INa densities [79].
Progressive cardiac conduction disease
PCCD (also called Lev or Lenègre disease) manifests as
progressive prolongation of the conduction parameters
(P wave, PR, and QRS intervals), and right or left bundle
branch block, without ST segment elevation or QT interval
prolongation (Fig. 8). A complete atrioventricular block
may develop and cause syncope or sudden death. The ECG
changes indicate slowing of electrical conduction through
the atria, atrioventricular node, His bundle, Purkinje fibers,
and ventricles, accompanied by an age-related degenerative
process, in which fibrosis affects only the cardiac conduction
system. In heritable PCCD, conduction slowing may be
attributed to loss-of-function mutations in SCN5A. The
mutations are reported to reduce INa by decreasing the
expression of channel proteins on the sarcolemma, expressing
non-functionalchannels,oralteringthegatingproperties(e.g.,
delayed activation, earlier inactivation, enhanced slow inacti-
vation, or slower recovery from inactivation) [63, 67, 75, 93].
These loss-of-function mechanisms are also described for
BrS-linked SCN5A mutations (Fig. 7). Moreover, a single
SCN5A mutation may cause PCCD alone (isolated) or PCCD
combined with BrS (overlap syndrome) [35, 73]. This
suggests that, in addition to INa reduction, which is enough
to cause conduction slowing in PCCD or BrS, other factors
are required for the development of the typical right-
precordial ST segment elevation in BrS.
Whether the age-dependent fibrosis of the conduction
system is a primary degenerative process in PCCD, or a
physiologic process that is accelerated by INa reduction
remains to be investigated. However, the latter is suggested
by histological studies, in which fibrosis was found in
cardiac biopsies of BrS patients [24], and animal studies in
heterozygous SCN5A knockout mice (50% INa reduction),
in which conduction defects and myocardial fibrosis that
deteriorated progressively with age were observed [65]. So
far, no molecular therapy for PCCD exists and the
implantation of a pacemaker is the most effective treatment.
PCCD and mutations in sodium channel regulatory proteins
Two loss-of-function mutations in SCN1B have been
identified in patients with PCCD who carried no mutation
in SCN5A. One mutation resulted in truncated β1-subunits
that failed to interact with Nav1.5 proteins, to increase INa
densities and to alter the gating properties as normal β1-
subunits did. The other mutation decreased the ability of
normal β1-subunits to increase INa densities and to facilitate
the activation of the co-expressed sodium channels [89].
Interestingly, normal and mutant β1-subunits were expressed
to a higher degree in the Purkinje fibers than in the
ventricles. This indicates that INa reduction in Purkinje fiber
myocytes may underlie prolongation of PR and QRS
intervals, and right or left bundle branch block in PCCD.
Dilated cardiomyopathy
DCM is characterized by ventricular dilatation and impaired
systolic function, which may proceed into congestive heart
failure. Although DCM is a final common pathway of various
acquired diseases, up to 50% of cases are reported to be
idiopathic (i.e., without any obvious aetiological trigger).
Approximately 20% ofidiopathicDCM cases display familial
prevalence, and have been linked to mutations in various
genes that encode proteins involved in the contractile
apparatus and the cytoskeleton. Initially, linkage analysis in
a largefamilywithDCM mappedthe disease locustoa region
on the short arm of chromosome 3 (3p22-p25), which harbors
the SCN5A gene [55]. Afterwards, a missense mutation in
Fig. 8 Prolonged conduction parameters (P wave, PR and QRS
intervals), and right bundle branch block in an individual with
progressive cardiac conduction disease
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family [47]. Since then, several other missense and truncation
mutations in SCN5A have been linked to DCM [25, 53, 56].
Remarkably, most of these mutations are found in patients
who display multiple phenotypes, including DCM, sinoatrial
node dysfunction, atrial flutter, atrial fibrillation, atrioventric-
ular block, bundle branch block, ventricular tachycardia, and/
or ventricular fibrillation. When expressed heterologously,
DCM-linked SCN5A mutations usually do not disrupt the
sarcolemmal expression of channel proteins, but cause
diverse loss-of-function and gain-of-function changes in their
gating properties (e.g., earlier or delayed activation, earlier
inactivation, disrupted fast inactivation, and increased INaL or
window current) [25, 53]. Although it remains unclear how
such divergent gating changes lead to DCM, it is speculated
that SCN5A mutations in DCM disrupt the interactions
between cardiac sodium channels and intracellular (or
extracellular) proteins that are essential for normal cardio-
myocyte structure and architecture. However, it must be
noted that mutations linked to DCM cases with conduction
defects often cause INa reduction. This is supported by
reduced SCN5A gene transcription and INa densities in a
mouse model with DCM that also displayed prolonged
conduction parameters [28]. No molecular therapy for DCM
exists, and the standard therapy for congestive heart failure is
applied.
Sick sinus syndrome
SSS encompasses various forms of arrhythmia that result
from sinoatrial node dysfunction. Arrhythmias may be
transient, are diagnosed electrocardiographically, and in-
clude sinus bradycardia, sinus arrest, and atrial tachycardia–
bradycardia syndrome (i.e., atrial tachycardia alternating
with episodes of sinus bradycardia; Fig. 9). Patients may
suffer from syncope and require lifelong pacemaker
therapy. Heritable SSS is associated with loss-of-function
mutations in SCN5A, and often linked to compound
heterozygous mutations in patients with severe symptoms
at relatively young age [14]. INa reduction results from
decreased sarcolemmal expression of mutant channel
proteins, expression of non-functional channels, and altered
gating properties (e.g., delayed activation, earlier inactiva-
tion; Fig. 7)[ 14, 37]. Not surprisingly, SSS may manifest
concomitantly with other phenotypes that are linked to
SCN5A loss-of-function mutations (i.e., BrS, PCCD) [37,
44, 73].
Pacemaker cells in the sinoatrial node reach the voltage
range for the sodium window current during action
potential phase 4. The small inward window current
contributes to the gradual depolarization of the sarcolemma
of these cells, and allows spontaneous action potential
generation, which underlies cardiac automaticity. In addition
to their contribution to cardiac pacemaker activity, sodium
channels also play an essential role in the propagation of
action potentials from the central area of the sinoatrial node
through its peripheral regions to the surrounding atrial muscle
[37, 84]. Experimental studies in heterozygous SCN5A
knockout mice suggest that the main mechanism of INa
reduction to cause SSS indeed involves reduced automaticity,
and conduction slowing or blocking of action potentials from
the sinoatrial node to the surrounding atrial muscle [36].
Interestingly, LQT-3 patients with SCN5A gain-of-function
mutations may also suffer from sinus bradycardia and sinus
arrest. Computer simulation models showed that Isus in
pacemaker cells may decrease sinus rate and induce sinus
arrest by delaying the repolarization and prolonging action
potential durations [83].
Atrial fibrillation
AFib is the most prevalent clinically relevant cardiac
arrhythmia, and is characterized by a disorganized electrical
activation of the atria. It usually affects elderly patients with
structural heart disease. However, AFib may also occur in
young patients with structurally normal hearts (i.e., lone
AFib), and display a familial occurrence. SCN5A mutations
were first linked to lone AFib in patients with DCM [56].
Next, a common polymorphism (H558R) in SCN5A was
found more often in patients with lone AF than matched
controls. Of note, H558R is known to reduce INa in
heterologous systems [18]. Subsequently, an SCN5A loss-
of-function mutation was identified in a family with lone
AFib [23]. It was speculated that INa reduction may
predispose to AFib by slowing the electrical conduction
velocity. Conduction slowing is an essential determinant for
Fig. 9 Sinus arrest in an
individual with sick sinus
syndrome. The patient also
suffered from sinus bradycardia
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mechanism is supported by an increased prevalence of lone
AFib, accompanied with prolonged atrial conduction
intervals (e.g., P wave duration), in BrS patients [34].
Nevertheless, two SCN5A gain-of-function mutations have
also been linked to lone AFib. Interestingly, both mutations
were found to induce gain-of-function by delaying channel
inactivation [38, 43]. In one mutation, larger INa densities
corresponded with increased atrial excitability in mutation
carriers [43]. The other mutation induced spontaneous
action potential formation when expressed in atrial cardio-
myocytes [38]. Thus, loss-of-function mutations in SCN5A
predispose to AFib by facilitating the maintenance of
reentrant excitation waves, while gain-of-function mutations
may initiate AFib by increasing atrial excitability.
Although both gain-of-function mutations discussed
above did not prolong QT intervals, another SCN5A gain-
of-function mutation has recently been described in a
family with LQT-3 and lone AFib. The mutation was
shown to induce gain-of-function by causing Isus,s u g g e s t i n g
that Isus may promote AFib by prolonging action potential
duration and triggering EADs. Importantly, through inhibi-
tion of Isus, flecainide not only shortened the QT intervals in
the affected family members, but also effectively restored the
normal sinus rhythm [12]. In contrast, flecainide therapy in
patients with AFib due to SCN5A loss-of-function mutations
may be contraindicated, because flecainide also blocks the
peak INa, and therefore may aggravate INa reduction in these
patients.
AFib and mutations in sodium channel regulatory proteins
Recently, mutations in SCN1B and SCN2B (encoding the
β1- and β2-subunits of the cardiac sodium channel,
respectively) have been identified in patients with lone
AFib. Interestingly, the reported patients with AFib and
mutations in SCN1B or SCN2B often displayed an ECG
pattern suspect for BrS. When heterologously co-expressed
with SCN5A, the mutant β1-subunits failed to increase INa
as normal β1-subunits did, and caused delayed channel
activation. Mutant β2-subunits also induced loss-of-
function, but only by delaying channel activation [88].
Sudden infant death syndrome
SIDS is diagnosed when an infant under the age of 1 year
suddenly and unexpectedly dies, and when a detailed
review of the clinical history, extensive examination of the
death scene, and a complete medical autopsy fail to provide
an explanation for the death. Although various exogenous
factors are recognized to increase the risk for SIDS (e.g.,
tobacco and alcohol use by the mother, low socioeconomic
status, prone sleeping), higher SIDS rates in some ethnic-
ities suggest a role for genetic factors in the development of
SIDS. Initially, this suggestion was reinforced when SIDS
was linked to prolonged repolarization intervals as seen in
LQTS [71]. This was followed by anecdotal reports linking
SIDS to gain-of-function mutations in SCN5A and to
mutations that were previously associated with LQT-3
[68, 90]. Subsequently, postmortem genetic testing in a
population-based cohort indicated that gain-of-function
mutations in SCN5A may be the most prevalent genetic
cause of SIDS [8]. SCN5A mutations in SIDS commonly
increase Isus, mostly in combination with altered gating
properties that result in INa gain-of-function (e.g., earlier
activation, delayed inactivation, or increased window
current). Interestingly, some SIDS-linked SCN5A mutations
display only Isus under acidic conditions, supporting the
role of exogenous factors (here acidosis) in the development
of SIDS [85]. Less frequently, SCN5A loss-of-function
mutations have also been found in infants with SIDS [57].
However, it may be possible that in these patients SIDS
represents a severe form of BrS that manifests during early
childhood [62].
SIDS and mutations in sodium channel regulatory proteins
Recently, postmortem genetic testing in population-based
cohorts identified mutations in CAV3 and GPD1-L as
possible causative genetic factors in the development of
SIDS [20, 80]. As mentioned earlier, mutations in CAV3 are
linked to LQT-9, and mutations in GDPL-1 are found in
patients with BrS [39, 81]. When co-expressed heterolo-
gously with SCN5A, SIDS-linked mutations in CAV3 or
GDPL-1 exerted similar effects on the cardiac sodium
channel as their equivalents in LQT-9 or BrS, respectively
(i.e., increased Isus in the presence of mutant CAV3
proteins, and decreased peak INa in the presence of mutant
GDPL-1 proteins). These data support the hypothesis that
SIDS may be a severe form of LQTS or BrS during infancy.
Overlap syndromes
Overlap syndromes involve overlapping clinical symptoms
or arrhythmias of various arrhythmogenic diseases (i.e.,
sodium channelopathies). The designation is also used
when a mutation causes various arrhythmogenic pheno-
types in different families or members of one family. Not
surprisingly, SCN5A loss-of-function mutations have often
been associated with overlapping phenotypes of BrS and
PCCD or BrS and SSS [15, 35, 42, 44, 73, 83]. Since
the underlying molecular mechanisms of these diseases
implicate INa reduction, it is plausible that the clinical
phenotype is determined by the degree of INa reduction, the
Pflugers Arch - Eur J Physiol (2010) 460:223–237 233nature of altered gating properties, the presence of
exogenous factors (e.g., electrolyte imbalance, drugs,
hormones, body temperature, subclinical cardiac structural
changes) and co-inherited genetic variants (e.g., polymor-
phisms in SCN5A or genes encoding regulatory proteins).
More surprisingly, some SCN5A mutations cause symp-
toms of both LQT-3 (INa gain-of-function) and BrS (INa
loss-of-function) in members of one family, or LQT-3 in
one family and BrS in another [15, 26, 42]. Although
exogenous and genetic factors discussed before may play a
role, such mutations are believed to alter gating properties
in a manner that results in both INa gain-of-function and
loss-of-function. For example, the insertion of an aspartic
acid residue at position 1795 of the Nav1.5 protein
(1795insD) was the first mutation found in a multigenera-
tional family with ECG signs of both LQT-3 and BrS [15].
While QT interval prolongation was found to be caused by
an increased Isus, BrS was shown to be the result of delayed
activation, earlier inactivation, and slower recovery from
inactivation of the mutant channels [82]. Interestingly, while
SCN5A mutations that are linked to LQT-3 often lead to
increased Isus levels, mutations linked to overlap syndromes
(LQT-3 and BrS with or without SSS) usually also induce
earlier inactivation (i.e., inactivation at more negative
membrane potentials) and enhanced tonic block by flecainide
[42]. Finally, administration of sodium channel blocking
drugs may induce typical ECG signs of BrS in patients with
LQT-3, limiting the use of such drugs to inhibit Isus and
restore delayed repolarization in these patients [61].
Conclusion
Cardiac sodium channelopathies that are described in this
review emphasize the importance of INa for normal cardiac
electrical activity. The association of most channelopathies
to mutations not only in SCN5A but also in genes encoding
the β-subunits or regulatory proteins indicates that, for
normal functioning of the cardiac sodium channel, the
contribution of various channel subunits is required. Most
of our understanding of the molecular mechanisms of
cardiac sodium channelopathies originates from experimental
studies in heterologous expression system and transgenic
mouse models. Although these models have greatly increased
our knowledge of the structure and function of the cardiac
sodium channel in normal hearts, and the nature and role of
INa dysfunction in diseased hearts, they have by and large
failed to explain the mechanism of different phenotypes or
diseases caused by one single mutation in SCN5A. Since the
native environment of cardiomyocytes is absent, the effects
of intracellular and extracellular molecules on the function of
cardiac sodium channels are greatly lost in heterologous
expression models. Although this shortcoming is remedied in
transgenic mouse models, the absence of environmental
factors and co-inherited genetic variants (e.g., polymor-
phisms, mutations in non-coding genetic regions) in mouse
models remains a limitation. These limitations compel
careful interpretation of the experimental data and their
translation into the patient phenotypes, and make it clear that
future research is needed to design more appropriate
expression systems (e.g., cardiomyocytes derived from
induced pluripotent stem cells). Future research is also
needed to discover novel gene-specific and mutation-
specific pharmacological therapies in the management of
cardiac sodium channelopathies. Currently, molecular therapy
for cardiac sodium channelopathies due to INa loss-of-
function is lacking, and the efficiency of sodium channel
blocking drugs to restore QT intervals in patients with LQT-3
seems to be limited to mutations that induce earlier
inactivation of the sodium channels.
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